Genomics

Genomics Projects

Our genomics R&D centers in Seattle and Shenzhen are working on a variety of in vitro assays that can be used in cancer research. These assays are made possible through our advanced clinical laboratory protocols and our bioinformatics team. Our primary focus is on Next Generation Sequencing (NGS) from tissues and body fluids (plasma, urine, etc).

 

Clinical Applications

Tumor neo-antigen burden (TNB) analysis

  • >1,000 genes that span > 1.0 Mb of the genome
  • Optimized for Chinese populations (HLA-typing)

Pan-cancer somatic mutation analysis

Whole exon sequencing of 127 cancer-related genes targeting 12 cancers

  • Breast adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, uterine corpus endometrial carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, colon carcinoma, rectal carcinoma, bladder urothelial carcinoma, kidney renal clear cell carcinoma, ovarian serous carcinoma, and acute myeloid leukemia

Lung cancer

  • 16 genes that are highly relevant to lung cancer
  • 8 genes that are FDA/NCCN recognized actionable mutations and biomarkers
  • 6 genes that are undergoing clinical trials and studies for targeted therapies
  • 2 gene with strong preclinical evidence

Lung cancer methylation detection using RT-PCR

  • Detection of methylation of SHOX2, HOXA9, and TAC1
  • These genes have been shown to be methylated in lung cancer patients

Breast cancer

  • 14 genes that are FDA/CFDA/NCCN recognized actionable mutations and biomarkers

BRCA1/2 mutation analysis

  • Highly mutated genes highly associated with breast cancer and other cancers
  • Germline mutation detection
Breast 21 RT-PCR based test for node-negative early stage breast cancer

  • Detection of 21 genes that are NCCN-recognized for breast cancer
  • Recurrence score calculated to aid treatment decisions

Colorectal cancer

  • 14 genes that are highly relevant to colorectal cancer
  • 8 genes that are a NCCN-recognized disease indicator
  • 3 genes that are a NCCN-recognized actionable mutation
  • 7 genes that are undergoing clinical trials and studies for targeted therapies

Colorectal cancer methylation detection using RT-PCR

  • Detection of methylation of SEPT9
  • Methylation of SEPT9 is an FDA approved biomarker for colorectal cancer